Pharma Mar SAU (PHMMF)
Pharma Mar, S.A. is a Madrid-based biopharmaceutical company focused on oncology and RNA interference. The company’s activities include research, development, production, and commercialization of bioactive compounds used in cancer care, with operations spanning Spain, several European markets, the United States, and other international regions. Its oncology portfolio includes Yondelis for soft tissue sarcoma and ovarian cancer, Zepzelca for small cell lung cancer, and Aplidin for multiple myeloma. Pharma Mar is also advancing several clinical-stage programs, including LAGOON and SaLuDo in Phase III, PM534 and PM54 in Phase I, and SYL1801 in Phase II. In addition, the company works on products designed to reduce or silence gene expression.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-PHMM.F
|
$95.81
|
11.3% Upside
|
Fair
|
—
|
—
|
—
|
Great
|
—
|
—
|
—
|
0.0%
|
July 29, 2026
|
16.3x
|
5.3x
|
5.8x
|
1.503 B
|
1.378 B
|
3.5%
|
77.3%
|
11.5
|
17.3%
|
75.4%
|
